載入中
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
前收盤價
US$1.08
−US$0.03 · -2.70%
盤後
US$1.08
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
日內區間
目前US$1.08
52週區間
目前US$1.08
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
90
深度低估
情緒
55
多空交錯
風險
75
高風險
動能
28
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
日內區間
目前US$1.08
52週區間
目前US$1.08
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8027.5萬 USD | 6930萬 USD | 5845.3萬 USD | 4141.8萬 USD | 2946.3萬 USD |
| 銷貨成本 | 2593.4萬 USD | 2281.2萬 USD | 1834.1萬 USD | 1437.4萬 USD | 1065萬 USD |
| 毛利 | 5434.1萬 USD | 4648.8萬 USD | 4011.2萬 USD | 2704.4萬 USD | 1881.3萬 USD |
| 研究與開發 | 922萬 USD | 881.3萬 USD | 961.9萬 USD | 893.7萬 USD | 674.3萬 USD |
| 銷售、一般及管理費用 | 7887.6萬 USD | 7937萬 USD | 7456.8萬 USD | 5711.4萬 USD | 4152.1萬 USD |
| 營業費用 | 8809.6萬 USD | 8060.3萬 USD | 8418.7萬 USD | 6605.1萬 USD | 4826.4萬 USD |
| 利息支出 | 524.5萬 USD | 529萬 USD | 522.3萬 USD | 405.1萬 USD | 359.7萬 USD |
| 折舊和攤銷 | 101萬 USD | 101.2萬 USD | 80.8萬 USD | 118.7萬 USD | 53.5萬 USD |
| 營業利益 | −3375.5萬 USD | −3411.5萬 USD | −4407.5萬 USD | −3900.7萬 USD | −2945.1萬 USD |
| 淨利 | −3883.1萬 USD | −3784.1萬 USD | −4666.4萬 USD | −4429.6萬 USD | −3327.6萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
